PhRMA Continues Critique of ICER Drug Pricing Studies

The Pharmaceutical Research and manufacturers of America (PhRMA) have repeatedly spoken out against the cost-effectiveness studies published by the Institute for Clinical and Economic Review (ICER) and has recently publicized its own four pointed list of recommendations to ICER. Read more here. (Source: Joe Cantlupe, BioPharma DIVE, 9/29/16)

You might also be interested in:

ICER Using New Economic Modeling Platform for Value Assessment August 24, 2018
PAI and BresMed Join Forces to Support Expanded Use of More… July 22, 2019
Review of Influence: The Institute for Clinical and Economic Review February 26, 2019
The Utility of ICER Reports for Private Payer Drug Coverage… September 19, 2018
ICER Provides Policy Recommendations for Opioid Use Disorder Therapies December 3, 2018
ICER Releases Report on Therapies for Long-term Prophylaxis HAE November 16, 2018
Lilly Releases Report Detailing Humalog U100 Pricing March 25, 2019